Company profile
ViiV Healthcare
Privately held: no public share price
Assets
(13 total)
13Total Assets
6Approved
4Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Cabotegravir(Vocabria / Cabenuva / Apretude) | Approved | HIV integraseSmall molecule | HIV |
Dolutegravir(Tivicay / Triumeq / Dovato / Juluca (component)) | Approved | HIV integraseSmall molecule | HIV |
Fosamprenavir(Lexiva / Telzir) | Approved | HIV proteaseSmall molecule | HIV |
Fostemsavir(Rukobia) | Approved | HIV gp120Small molecule | HIV |
Maraviroc(Selzentry / Celsentri) | Approved | CCR5 co-receptorSmall molecule | HIV |
Rilpivirine(Edurant) | Approved | HIV reverse transcriptaseSmall molecule | HIVAtherosclerotic Cardiovascular Disease |
| Phase 3 | HIV envelopeMonoclonal antibody | HIV | |
| Phase 3 | HIV capsidSmall molecule | HIV | |
| Phase 3 | HIV capsidSmall molecule | HIV | |
| Phase 3 | HIV integraseSmall molecule | HIV | |
| Phase 2 | HIV-1 Gag maturation (CA-SP1 cleavage)Small molecule | HIV | |
| Phase 1 | HIV capsidMultispecific antibody | HIV | |
| Phase 1 | Undisclosed / early pipelineSmall molecule | HIV |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.